Literature DB >> 30721102

2017 ATA guidelines on the management of thyroid dysfunctions in pregnancy: what do OB/GYNs need to know?

Mario Rotondi1, Valentina Capelli1, Luca Chiovato1, Rossella E Nappi2.   

Abstract

In the past two decades, the issue of thyroid dysfunctions during pregnancy and the postpartum period received increasing attention by both endocrinologists and obstetrics/gynecologists (OB/GYNs), the latter often became the first to diagnose an impaired thyroid function in pregnant women. In this setting, a series of different clinical guidelines have been published and reviewed, the latest ones being represented by the 2017 ATA guidelines, which extensively address a wide variety of topics, including iodine supplementation, thyroid autoimmunity, hyper- and hypo-thyroidism, thyroid nodules and cancer, post-partum management, as well as the need for pre-conception screening. Aim of this editorial is to offer a practical guidance to the OB/GYN reader by focusing upon evidence-based changes introduced by the latest guidelines, with particular regard to: (a) prescribing further endocrine testing before referral; (b) providing evidence-based answers to some of the frequently asked questions.

Entities:  

Keywords:  Thyroid; guidelines; hypothyroidism; pregnancy; screening

Mesh:

Substances:

Year:  2019        PMID: 30721102     DOI: 10.1080/09513590.2018.1532496

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  2 in total

1.  Factors Associated with Thyroid Disorders and Iodine Adequacy in Pregnant Saudi Women.

Authors:  Bassem Refaat; Firas Azzeh
Journal:  Biol Trace Elem Res       Date:  2020-07-25       Impact factor: 3.738

2.  The targeted high-risk case-finding approach versus universal screening for thyroid dysfunction during pregnancy: thyroid-stimulating hormone (TSH) and/or thyroid peroxidase antibody (TPOAb) test?

Authors:  S Nazarpour; M Amiri; F Ramezani Tehrani; A Sheidaei; F Azizi
Journal:  J Endocrinol Invest       Date:  2022-04-02       Impact factor: 5.467

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.